Boston Scientific Ramping Up Internal R&D; Medinol Claims Infringement
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's R&D spending is expected to jump roughly 16% to $230 mil. in 2001, reflecting the firm's increased commitment to in-house innovation as opposed to relying primarily on acquisitions to build its product pipeline.